Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMY6V5T)

Drug Name
ICasp9M28z T cell Drug Info
Indication
Disease Entry ICD 11 Status REF
Lung cancer 2C25.0 Phase 1 [1]
Malignant pleural effusion 2D72 Phase 1 [1]
Mesothelioma 2C51.2 Phase 1 [1]
Metastatic malignant neoplasm 2D50-2E09 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMY6V5T

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN CAR-T-Cell-Therapy [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Mesothelin (MSLN) DTT MSLN -0.515 2.233 -0.152 0
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Lung cancer
ICD Disease Classification 2C25.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mesothelin (MSLN) DTT MSLN 2.86E-20 3.98 6.12
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02414269) Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin